TMO (STOCKS)
Thermo Fisher Scientific, Inc.
$514.230000
+18.120000 (+3.65%)
Prev close: $496.110000
Company Information
- Exchange
- XNYS
- Sector
- Health Technology
- Industry
- Medical Specialties
- CEO
- Marc N. Casper
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $191,032.06M
- Employees
- 125,000
- P/E (TTM)
- 27.97
- P/B (TTM)
- 3.49
- Dividend Yield
- 35.48%
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
11
Strong Buy
20
Buy
4
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Dec 2025 (Q4)
|
$6.57 | $6.51 | +0.0594 | +0.91% |
|
Sep 2025 (Q3)
|
$5.79 | $5.55 | +0.2422 | +4.37% |
|
Jun 2025 (Q2)
|
$5.36 | $5.28 | +0.0847 | +1.61% |
|
Mar 2025 (Q1)
|
$5.15 | $5.15 | -0.0035 | -0.07% |
Financial Statements
| Revenues | $44.56B |
| Benefits Costs and Expenses | $37.25B |
| Costs And Expenses | $36.81B |
| Operating Expenses | $36.81B |
| Selling, General, and Administrative Expenses | $8.73B |
| Research and Development | $1.40B |
| Other Operating Expenses | $26.68B |
| Operating Income/Loss | $7.75B |
| Income/Loss Before Equity Method Investments | $7.31B |
| Income/Loss From Continuing Operations After Tax | $6.76B |
| Income/Loss From Continuing Operations Before Tax | $7.31B |
| Income/Loss From Equity Method Investments | -$41.00M |
| Income Tax Expense/Benefit | $547.00M |
| Income Tax Expense/Benefit, Current | $1.19B |
| Income Tax Expense/Benefit, Deferred | -$639.00M |
| Net Income/Loss | $6.72B |
| Net Income/Loss Attributable To Noncontrolling Interest | $17.00M |
| Net Income/Loss Attributable To Parent | $6.70B |
| Net Income/Loss Attributable To Redeemable Noncontrolling Interest | $17.00M |
| Net Income/Loss Available To Common Stockholders, Basic | $6.70B |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | $17.77 |
| Diluted Earnings Per Share | $17.74 |
| Basic Average Shares | 377,000,000 |
| Diluted Average Shares | 378,000,000 |
| Assets | $110.34B |
| Current Assets | $28.71B |
| Inventory | $5.43B |
| Other Current Assets | $23.28B |
| Noncurrent Assets | $81.64B |
| Fixed Assets | $10.57B |
| Intangible Assets | $15.84B |
| Other Non-current Assets | $55.23B |
| Liabilities | $56.93B |
| Current Liabilities | $15.19B |
| Accounts Payable | $3.62B |
| Wages | $2.00B |
| Other Current Liabilities | $9.57B |
| Noncurrent Liabilities | $41.74B |
| Long-term Debt | $39.17B |
| Other Non-current Liabilities | $2.57B |
| Redeemable Noncontrolling Interest | $122.00M |
| Equity | $53.42B |
| Equity Attributable To Noncontrolling Interest | $7.00M |
| Equity Attributable To Parent | $53.41B |
| Temporary Equity | $122.00M |
| Liabilities And Equity | $110.34B |
| Net Cash Flow From Operating Activities | $7.82B |
| Net Cash Flow From Operating Activities, Continuing | $7.82B |
| Net Cash Flow From Investing Activities | -$4.05B |
| Net Cash Flow From Investing Activities, Continuing | -$4.05B |
| Net Cash Flow From Financing Activities | $1.80B |
| Net Cash Flow From Financing Activities, Continuing | $1.80B |
| Net Cash Flow | $5.57B |
| Net Cash Flow, Continuing | $5.57B |
| Comprehensive Income/Loss | $6.97B |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $17.00M |
| Comprehensive Income/Loss Attributable To Parent | $6.95B |
| Other Comprehensive Income/Loss | $249.00M |